Continuation of the Drug Induced Liver Injury Network (DILIN)

May 2021 Council

Lead Division/Office


Point(s) of Contact

Jose Serrano, M.D., Ph.D.

Executive Summary

Drug Induced Liver Injury (DILI) is the most common cause of acute liver failure in the US and the major reason for the FDA not to approve or to withdraw drugs from the US market, limiting therapeutic alternatives for patients. The Drug Induced Liver Injury Network (DILIN) is the only structured, systematic and comprehensive effort to characterize DILI in the world. The Network has made major advances in the understanding of the clinical presentation and outcomes of DILI as well as exploratory inroads on the pathogenesis of DILI.  With the infrastructure and knowledge gained, a renewed Network will continue to produce and publish the largest and most comprehensive body of information on DILI, enhancing our understanding of DILI and providing clinicians with unbiased epidemiological, clinical and genetic information on DILI and possible means of its prevention, treatment and control.